IFM Investors Pty Ltd Takes $2.24 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

IFM Investors Pty Ltd purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 9,742 shares of the biotechnology company’s stock, valued at approximately $2,238,000.

A number of other institutional investors have also made changes to their positions in the stock. First Trust Direct Indexing L.P. boosted its stake in United Therapeutics by 38.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company’s stock worth $484,000 after acquiring an additional 580 shares during the last quarter. State of Alaska Department of Revenue boosted its position in shares of United Therapeutics by 153.5% during the first quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock worth $3,802,000 after purchasing an additional 10,025 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of United Therapeutics by 0.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company’s stock worth $23,211,000 after purchasing an additional 338 shares in the last quarter. MBM Wealth Consultants LLC grew its holdings in shares of United Therapeutics by 2.7% in the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after buying an additional 59 shares during the period. Finally, State of Michigan Retirement System increased its position in shares of United Therapeutics by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 12,232 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 300 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total transaction of $859,716.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $31,045.30. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total transaction of $859,716.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $31,045.30. The disclosure for this sale can be found here. Insiders have sold a total of 136,990 shares of company stock valued at $32,239,641 in the last three months. 12.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on UTHR shares. SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Wedbush reissued an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Stock Down 0.9 %

Shares of NASDAQ UTHR traded down $2.10 during mid-day trading on Friday, hitting $233.85. The company had a trading volume of 369,691 shares, compared to its average volume of 473,041. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $233.74 and a two-hundred day simple moving average of $228.81. The company has a market capitalization of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The firm had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. During the same quarter last year, the company posted $2.67 earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.